00570 TRAD CHI MED
- 4.240
- +0.070+1.68%
TRAD CHI MED News
China TCM Holdings' H1 Profit Falls 64% as Revenue Slips 10%
Trad chi med (00570.HK): Traditional Chinese medicine 3.1 ancient classic prescription compound preparation Angelica blood-enriching soup granules approved for market.
Economic Daily 29th August|Traditional Chinese med (00570.HK) announced that the first traditional Chinese medicine compound preparation managed according to the ancient classic prescription catalogue (i.e., the 3.1 category new pharmaceutical of trad chi med) Angelica Sinensis Compound Granules ("the pharmaceutical") has been approved for marketing by the National Medical Products Administration of China, and the pharmaceutical marketing license holder is Guangdong Global Pharmaceutical Co., Ltd., an affiliate of the company. The pharmaceutical was independently developed by the group and the prescription originated from the "Identification of Internal and External Injuries." Angelica Sinensis Compound Granules ("the prescription") has the function of tonifying qi and nourishing blood, and it is the first domestically approved classic traditional Chinese medicine prescription based on this prescription. The approval and marketing of the pharmaceutical signifies the group's.
Express News | China Traditional Chinese Medicine - Danggui Buxue Tang Granules Approved for Marketing by Nmpa
trad chi med released its interim performance, with shareholders' share of net profit of 0.211 billion yuan, a year-on-year decrease of 63.5%.
Trad chi med (00570) released its interim performance for the six months ending June 30, 2024. The group achieved a total revenue of RMB 8.385 billion, a decrease of 9.9% year-on-year. The company's equity holders should account for a surplus of RMB 0.211 billion, a decrease of 63.5% year-on-year. Basic earnings per share were 4.19 cents.
Express News | China Traditional Chinese Medicine - Hy Profit Attributable RMB211 Mln
Express News | China Traditional Chinese Medicine Holdings - No Dividend Was Proposed for Six Months
TRAD CHI MED: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
Trad Chi Med (00570.HK) has appointed Jia Lin Capital as its independent financial advisor.
Glory harvest on August 26, trad chi med (00570.HK) announced that Jiarin Capital Limited (a licensed entity under the Securities and Futures Ordinance to provide opinions on institutional financing) has been appointed as an independent financial advisor to provide advice to the independent directors’ committee, and in accordance with Rule 2.1 of the Takeovers Code, the appointment has been approved by the independent directors’ committee.
Daiwa: Maintains a "shareholding" rating for trad chi med (00570), lowers target price to HKD 4.6.
HSBC will lower the profit forecast for China Traditional Medicine (00570) from 2024 to 2030 by 10 to 13%.
HK stocks abnormal movement | trad chi med (00570) fell nearly 3% after warning of profit decline, expecting a maximum year-on-year decrease of up to 70% in net income in the medium term.
After issuing a profit warning, shares of trad chi med (00570) fell nearly 3%. As of the time of writing, it fell 1.70% to HKD 4.05, with a turnover of 23.4676 million HKD.
Trad Chi Med (00570.HK) has received a shareholding of 6.6 million shares from Goldman Sachs.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on August 22, 2024, China Traditional Chinese Medicine (00570.HK) received a shareholding of 6.6 million shares with an average price of 4.10 Hong Kong dollars per share from The Goldman Sachs Group, Inc., with a total investment of approximately 27.06 million Hong Kong dollars. After the shareholding, The Goldman Sachs Group, Inc. now holds a total of 253,856,199 shares, with a shareholding ratio increasing from 4.91% to 5.04%.
trad chi med (00570.HK) is expected to see a year-on-year decline of 60%-70% in net income for the mid-term.
Gelonghui August 21st, trad chi med (00570.HK) announced that the company expects a 60%-70% year-on-year decrease in net income for the six months ending June 30, 2024, mainly due to: (1) the traditional chinese medicine formula granule business is affected by multiple factors such as price reductions in centralized procurement and increased market competition, leading to a decline in sales scale and profitability; (2) the increase in accounts receivable with long aging in this period leads to a year-on-year increase in credit impairment losses; and (3) the retroactive payment of taxes by some of the company's subsidiaries has a significant impact on the group's current net income.
trad chi med (00570) issued a profit warning, expected mid-term net income to decrease by 60% to 70% year-on-year.
Trad Chi Med (00570) announced in a statement that the group expects to achieve a net profit for the current period (six months ended June 30, 2024) ...
Express News | China Traditional Chinese Medicine - Expected Result Due to Decline in Sales and Profitability of Concentrated Tcm Granules Business, Others
Some subsidiary companies of trad chi med (00570) have paid a total of approximately 0.103 billion yuan in taxes.
Trad chi med (00570) announced that recently, some of its subsidiaries have been inspected by the local tax authorities...
Express News | China Traditional Chinese Medicine Sees Net Profit Decrease by 60%-70% for Six Months
TRAD CHI MED: INSIDE INFORMATIONPROFIT WARNING
Express News | China Traditional Chinese Medicine- Remedial Taxes in Aggregate of RMB102.8 Mln Has Been Paid Currently
Express News | China Traditional Chinese Medicine - Taxes Recognized Expected to Decrease Co's Net Profit Attributable for Year by RMB129.0 Mln
Express News | China Traditional Chinese Medicine - Remedial Taxes From 2017 to 2023 in Aggregate Amount of RMB153.4 Mln
Analysis
Price Target
No Data
